3rd Quarter - Report

CROSSROADS STRATEGIES, LLC for GENENTECH, INC.

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

S.959, Pharmaceutical Compounding Quality and Accountability Act; H.R.1416, Cancer Patient Protection Act of 2013; S.957, Drug Supply Chain Security Act; H.R.1919, Safeguarding America's Pharmaceuticals Act of 2013; compounding issues; pharma supply chain issues; Medicare reimbursement issues.

LobbyistCovered position, as disclosed
ANNE BRADY —
JOHN GREEN —
STEWART HALL —
MATHEW LAPINSKI —
HUNTER MOORHEAD —
STEVE TILTON —
TODD MATTHEW WEISS —
MATT WISE —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1416 (113th), S. 959 (113th), S. 957 (113th), H.R. 1919 (113th)

Budget/Appropriations BUD

Monitored H.J.RES.59, Continuing Appropriations Resolution, 2014.

LobbyistCovered position, as disclosed
ANNE BRADY —
JOHN GREEN —
STEWART HALL —
MATHEW LAPINSKI —
HUNTER MOORHEAD —
STEVE TILTON —
TODD MATTHEW WEISS —
MATT WISE —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.J.Res. 59 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.